Ibrutininb appears to be the most promising drug we have seen in Waldenstrom’s macroglobulinemia and will likely significantly change the therapeutic landscape,” according to Bruce Cheson, MD, Deputy Chief, Hematology-Oncology and Head of Hematology Research at Georgetown Lombardi Cancer Center in Washington, DC.
“The situation in [diffuse large B-cell lymphoma] is a bit more complicated,” he noted. “Ibrutinib has activity in one subtype of the disease—activated B-cell–type—but minimal activity in the other [non–germinal-center B-cell–type]. Even in the former, there are different mutations that respond more favorably than others. Certainly, not all [diffuse large B-cell lymphomas] are created equal. This clearly pushes the case for personalized therapeutic strategies.”
Disclosure: Dr. Cheson reported no potential conflicts of interest.
The Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) is changing the landscape of treatment in chronic lymphocytic leukemia. New research with the drug in lymphoma, presented at the 2013 American Society of Hematology (ASH) Annual Meeting in New Orleans, indicates it may be of benefit in...